Immix Biopharma (IMMX) Tax Provisions (2021 - 2026)
Immix Biopharma (IMMX) posted Tax Provisions of -$8.3 million for Q4 2025, down 107110.9% sequentially from $7722.0 in Q3 2025, and down 76719.21% YoY from N/an in Q4 2024.
Immix Biopharma (IMMX) Tax Provisions (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Tax Provisions for 5 years, with the latest figure at -$8.3 million in Q4 2025.
- Quarterly Tax Provisions fell 76719.21% year-over-year to -$8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.2 million (down 20171.94% YoY) and the FY2025 annual result came in at -$8.2 million, down 20171.94% from the prior year.
- Tax Provisions slipped to -$8.3 million in Q4 2025 per IMMX's latest filing, from $7722.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $11144.0 in Q3 2024 and troughed at -$8.3 million in Q4 2025.
- A 5-year average of -$711749.6 and a median of $3442.5 in 2022 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions tumbled 117995.06% in 2022, then jumped 307.12% in 2023.
- Over 5 years, Tax Provisions stood at $1477.0 in 2021, then sank by 117995.06% to -$1.7 million in 2022, then plunged by 148.5% to -$4.3 million in 2023, then jumped by 100.25% to $10785.0 in 2024, then sank by 76719.21% to -$8.3 million in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered -$8.3 million, $7722.0, and $8914.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 14,322.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14,322.00 |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | 7,722.00 |
| Jun 30, 2025 | 8,914.00 |
| Mar 31, 2025 | 9,822.00 |
| Dec 31, 2024 | 10,785.00 |
| Sep 30, 2024 | 11,144.00 |
| Jun 30, 2024 | 10,269.00 |
| Mar 31, 2024 | 8,839.00 |
| Dec 31, 2023 | -4.33 Mn |
| Sep 30, 2023 | 6,807.00 |
| Jun 30, 2023 | 6,349.00 |
| Mar 31, 2023 | 5,170.00 |
| Dec 31, 2022 | -1.74 Mn |
| Sep 30, 2022 | 1,672.00 |
| Jun 30, 2022 | 1,715.00 |
| Mar 31, 2022 | 1,622.00 |
| Dec 31, 2021 | 1,477.00 |
| Sep 30, 2021 | 1,337.00 |
| Jun 30, 2021 | 1,608.00 |